Journal of Visualized Experiments

Assessing Mineral Availability in Fish Feeds using Complementary Methods Demonstrated with the Example of Zinc in Atlantic Salmon --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video		
Manuscript Number:	JoVE59862R2		
Full Title:	Assessing Mineral Availability in Fish Feeds using Complementary Methods Demonstrated with the Example of Zinc in Atlantic Salmon		
Keywords:	Salmonids; Zinc; availability; in vitro; organic source; trace mineral; RTgutGC; speciation; fish		
Corresponding Author:	P. Antony Jesu Prabhu Havforskningsinstituttet Bergen, Bergen NORWAY		
Corresponding Author's Institution:	Havforskningsinstituttet		
Corresponding Author E-Mail:	Antony.Prabhu@hi.no		
Order of Authors:	Marta S Silva		
	Thea Stewart		
	Heidi Amlund		
	Jens J Sloth		
	Pedro Araujo		
	Erik-Jan Lock		
	Christer Hogstrand		
	Robin Ørnsrud		
	Rune Waagbø		
	P. Antony Jesu Prabhu		
Additional Information:			
Question	Response		
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)		
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	London		

1 TITLE:

2 Assessing Mineral Availability in Fish Feeds using Complementary Methods Demonstrated with

the Example of Zinc in Atlantic Salmon

5 **AUTHORS AND AFFILIATIONS:**

- 6 Marta S Silva^{1,2}, Thea Stewart⁴, Heidi Amlund^{1,3}, Jens J Sloth^{1,3}, Pedro Araujo¹, Erik-Jan Lock¹,
- 7 Christer Hogstrand⁴, Robin Ørnsrud¹, Rune Waagbø^{1,2}, Antony Jesu Prabhu^{1,*}

8 9

3

4

- ¹Institute of Marine Research, P.O. Box 1870 Nordnes, 5817 Bergen, Norway
- ²Department of Biological Sciences, University of Bergen, P.O. Box 7803, 5020 Bergen, Norway
- ³National Food Institute, Technical University of Denmark, Kemitorvet, Bygning 202, 2800 Kgs.
- 12 Lyngby, Denmark
- 13 ⁴Metal metabolism group, Nutritional Sciences Division, King's College London, Franklin-Wilkins
- 14 Building, 150 Stamford Street, London, SE1 9NH, United Kingdom

15 16

Corresponding author:

17 Antony Jesu Prabhu (antony.philip@hi.no)

18 19

Email addresses of co-authors:

- 20 Marta S Silva (marta.silva@hi.no)
- 21 Thea Stewart (theodora.stewart@kcl.ac.uk)
- 22 Heidi Amlund (haml@food.dtu.dk)23 Jens J Sloth (jjsl@food.dtu.dk)
- 24 Pedro Araujo (pedro.araujo@hi.no) 25 Erik-Jan Lock (erik-jan.lock@hi.no)
- 26 Christer Hogstrand (christer.hogstrand@kcl.ac.uk)
- 27 Robin Ørnsrud (robin.ornsrud@hi.no)28 Rune Waagbø (rune.waagbo@hi.no)

29 30

KEYWORDS:

Zinc, speciation, availability, aquaculture, uptake, mineral, Salmo salar

313233

34

35

36

SUMMARY:

This article explains in detail a systematic approach to assess micro-mineral availability in Atlantic salmon. The methodology includes tools and models with increasing biological complexity: (1) chemical speciation analysis, (2) in vitro solubility, (3) uptake studies in cell lines, and (4) in vivo fish studies.

373839

ABSTRACT:

- 40 Assessing the availability of dietary micro-minerals is a major challenge in mineral nutrition of
- 41 fish species. The present article aims to describe a systematic approach combining different
- 42 methodologies to assess the availability of zinc (Zn) in Atlantic salmon (Salmo salar). Considering
- 43 that several Zn chemical species can be present in an Atlantic salmon feed, it was hypothesised
- 44 that Zn availability is influenced by the Zn chemical species present in the feed. Thus, in this study,

the first protocol is about how to extract the different Zn chemical species from the feed and to analyze them by a size exclusion chromatography-inductively coupled plasma mass spectroscopy (SEC-ICP-MS) method. Subsequently, an in vitro method was developed to evaluate the solubility of dietary Zn in Atlantic salmon feeds. The third protocol describes the method to study the impact of changing Zn chemical species composition on the uptake of Zn in a fish intestinal epithelial model using a rainbow trout gut cell line (RTgutGC). Together, the findings from the in vitro methods were compared with an in vivo study examining the apparent availability of inorganic and organic sources of Zn supplemented to Atlantic salmon feeds. The results showed that several Zn chemical species can be found in feeds and the efficiency of an organic Zn source depends very much on the amino acid ligand used to chelate Zn. The findings of the in vitro methods had less correlation with that outcome of the in vivo study. Nevertheless, in vitro protocols described in this article provided crucial information regarding Zn availability and its assessment in fish feeds.

INTRODUCTION:

Fish meal and fish oil were traditionally used in Atlantic salmon feed. However, these ingredients are being increasingly replaced by plant-based ingredients¹. The aforementioned shift in feed composition has resulted in low dietary availability and an increased need for improving mineral availability in Atlantic salmon feeds, especially zinc (Zn)². The reduced availability might be a result of a change in the Zn level, Zn chemical species or/and antinutritional factors present in the feed matrix. In this scenario, a new array of additives generically considered as 'organic sources' have emerged with potential of being a better available source of dietary minerals to fish. Therefore, it is important to understand fundamental chemistry and physiology governing the availability of minerals and their sources to fish. Zinc is an essential trace element for all living organisms³. The role of Zn as a signaling molecule has been described at both the paracellular and intracellular level in fish⁴. In Atlantic salmon, Zn deficiency has been associated with skeletal abnormalities and reduced activity of various Zn metalloenzymes^{5,6}.

This study describes a systematic approach to understand Zn availability by categorizing it into four different compartments of varied chemical and biological complexity. The methods involved are described in four sections, as can be seen in **Figure 1**: (1) evaluation of Zn chemical species in the soluble fraction of an Atlantic salmon feed using a size exclusion chromatography-inductively coupled plasma mass spectroscopy (SEC-ICP-MS) method⁷; (2) in vitro solubility of supplemented Zn in Atlantic salmon feed; (3) evaluation Zn chemical species uptake by in vitro intestinal model (RTgutGC)⁸; and (4) apparent availability of Zn in Atlantic salmon (*Salmo salar*)⁹. Similar protocols can be developed for other minerals (e.g., manganese, selenium, copper) of nutritional interest to aquaculture fish species.

PROTOCOL:

The feeding trial in section 4 was performed according to Norwegian (FOR-2015-06 - 18-761) and European legislation (Directive 2010/63/EU).

1. Evaluation of Zn chemical species in the soluble fraction of an Atlantic salmon feed using a SEC-ICP-MS method

90 1.1. Extraction buffer (100 mM Tris-HCl, pH 8.5)

91

89

92 1.1.1. Prepare the extraction buffer by dissolving an appropriate amount of tris(hydroxymethyl)aminomethane to reach the desired ionic strength (100 mM) in ultrapure H_2O .

95

96 1.1.2. Adjust the pH of the solution to pH 8.5 with HCl solution, monitoring the pH change with a pH meter.

98 99

1.2. Preparation of feed samples

100

NOTE: The feed sample used was formulated based on commercial feed for Atlantic salmon, containing protein sources mainly from plant-based ingredients (i.e., approximately 5% fish protein, 10% fish oil, 68% plant-based protein and 12% plant-based oil). Zinc sulphate was supplemented to the feed.

105

106 1.2.1. Grind the feed sample by hand using a pestle and a mortar.

107

108 1.2.2. Sieve the feed sample to ensure that the extraction is performed in a feed fraction with similar particle size (from 850 µm to 1.12 mm).

110

111 1.2.3. Proceed to perform the Zn extraction.

112

113 1.3. Zinc extraction from a feed sample

114

1.3.1. Weigh approximately 0.5 g of feed in triplicate into 15 mL conical tubes.

116

1.3.2. Add the extraction buffer (5 mL of 100 mM Tris-HCl, pH 8.5) to the samples.

118

1.3.3. Extract the samples in a rotator (20 rpm) at 4 $^{\circ}$ C for 24 h.

120

1.3.4. Separate the soluble and non-soluble fractions by centrifugation for 10 min at 3000 x g.

122

1.3.5. Use a 0.45 μm disposable syringe filter to filter the soluble fraction.

124

1.3.6 Transfer the filtered samples to clean tubes.

126

1.3.7. Perform the Zn speciation analysis in the soluble fractions using SEC-ICP-MS, as described in step 1.6.

129

NOTE: A summary of the procedure for Zn extraction from a feed sample is described in **Figure**2.

132

1.4 Mobile phase solution (50 mM Tris-HCl + 3% MeOH, pH 7.5)

134

1.4.1. Prepare the mobile phase solution dissolving 6.057 g of tris(hydroxymethyl)aminomethane in 1 L of 3% MeOH solution (v/v).

137

1.4.2. Adjust the pH of the solution to pH to 7.5 with HCl solution, monitoring the pH change with a pH meter.

140

141 1.4.3. Filter the mobile phase solution through a 0.45 μm membrane filter.

142143

1.5. Molecular weight calibration of the SEC column separation range

144

1.5.1. Calibrate the separation range by performing a molecular weight calibration.

146

NOTEL: In this study thyroglobulin (660 kDa), Zn/Cu superoxide dismutase (32 kDa), myoglobin (17 kDa) and vitamin B12 (1.36 kDa) were used.

149

1.5.2. Prepare each of the standards with a known concentration in ultrapure H₂O.

151

152 1.5.3. Prepare a high-performance liquid chromatography (HPLC) vial by adding 250 μ L of standard to a vial.

154

1.5.4. Load the vials with standards to the sequence run of the samples.

156

1.5.4. Run the molecular weight calibration at the beginning and at the end of the analytical sequence, monitoring ¹²⁷I (thyroglobulin), ⁶⁶Zn (Zn/Cu superoxide dismutase), ⁵⁷Fe (myoglobin) and ⁵⁹Co (vitamin B12).

160

NOTE: The molecular weight calibration is simultaneously performed with the Zn speciation analysis.

163

164 1.6. Zinc speciation analysis using SEC-ICP-MS

165

NOTE: The Zn speciation analysis by the SEC-ICP-MS method was developed based on principles described elsewhere^{10,11} and further optimization was performed for the analysis of an Atlantic salmon feed⁷.

169

1.6.1. Perform the Zn speciation analysis on the soluble fractions by using a size exclusion chromatography (SEC) column and an HPLC coupled with inductively coupled plasma mass spectroscopy (ICP-MS).

173

1.6.2. Prepare an HPLC vial by adding 250 μ L of soluble fraction to a vial.

175

1.6.3. Before analysis, spike all the samples with 0.5 μL of vitamin B12. This step allows to correct

177 for retention times shifts, monitoring ⁵⁹Co.

178

1.6.4. Dilute the soluble fraction with extraction buffer (100 mM Tris-HCl, pH 8.5) and adjust to a final volume of 1 mL.

181

182 1.6.5. Prepare the sequence run of the samples in random order.

183

184 1.6.6. Tune the ICP-MS according to manufacturer's instructions.

185

1.6.7. Follow the instrument settings for the HPLC and ICP-MS performing the Zn speciation analysis (see **Table 1**).

188 189

2. In vitro solubility of supplemented Zn in Atlantic salmon feed

190

NOTE: The feed sample used was formulated based on commercial feed for Atlantic salmon, containing protein sources mainly from plant-based ingredients (i.e., approximately 5% fish meal, 10% fish oil, 68% plant-based ingredients and 12% vegetable oil).

194

2.1. Grind the Atlantic salmon feed samples for 10 s at 3000 rpm using a knife mill and store at 4 °C until further analysis.

197

2.2. Weigh ~0.2 g of the feed samples ground in step 2.1 and add Zn radiotracer (⁶⁵Zn) of known specific activity in a 5 mL volume sample tube (with a cap).

200

201 CAUTION: This procedure must be performed inside a radionuclide suite. The person performing 202 this step should be trained and certified to handle radio isotopes. The safety and precautionary 203 measures advised by the radiation safety administration of the institute must be strictly followed.

204

2.3. Then prepare the freshwater intestinal luminal buffer solution as described below.

206

2.3.1. For salt solution A, weigh 11.65 g of NaNO₃, 0.55 g of KNO₃ and 0.4 g of MgSO₄. Dissolve the salts in ultrapure H₂O and adjust to a final volume of 60 mL.

209

2.3.2. For salt solution B, weigh 0.31 g of $Ca(NO_3)_2 \cdot _4H_2O$. Dissolve the salts in ultrapure H_2O and adjust to a final volume of 10 mL.

212

2.3.3. Use 500 mM HEPES stock solution as salt solution C.

214

2.3.4. For salt solution D, weigh 1.2 g of $MgCl_2$, dissolve the salt in ultrapure H_2O and adjust to a final volume of 20 mL.

217

2.3.5. For salt solution E, weigh 0.9 g of MgSO₄, dissolve the salt in ultrapure H_2O and adjust to a final volume of 20 mL.

220

2.3.6. Prepare pyruvate solution by dissolving 0.55 g of CH₃COCOONa in 10 mL of ultrapure H₂O.

222

223 2.3.7. Dissolve 0.9 g of galactose ($C_6H_{12}O_6$) in ultrapure H_2O .

224

2.3.8. Dissolve well using a magnetic stirrer and sterilize salt solutions A, B, D and E by autoclaving, and solution C, pyruvate and galactose by filtration through a 200 μm syringe filter.

227

- 2.3.9. After preparation of the different stock solutions, to prepare 100 mL of working solution of the buffer, mix the above prepared solutions in the following proportion: 6.8 mL of salt solution
- A, 4.14 mL of B, 5 mL of C, 2.5 mL of D, 1.5 mL of E, and 1.14 mL each of pyruvate and galactose.
- 231 Make up the volume to 100 mL using deionized water.

232

NOTE: The above buffer will now represent the ionic composition of the intestinal lumen found in freshwater salmonids.

235

2.4. Prepare six other aliquots of the buffer described in step 2.6 and add one of the following amino acids (cysteine, methionine, glycine, histidine, lysine and arginine) to reach a final molar concentration of 5 mM.

239

240 2.5. Add the freshwater intestinal luminal buffer (reaction volume = 3 mL; pH 7.4) to the feed sample.

242

243 2.6. Repeat step 2.5 with the buffers described in 2.4 (in the presence of different amino acids at 5 mM concentration).

245

2.9. Close the tubes and allow them to spin in a rotary spinner for 30 min at 25 rpm.

247

2.10. Separate the soluble and non-soluble fractions by centrifuging for 10 min at 1157 x g.

249

250 2.12. Use a gamma teller to measure the counts per minute (cpm) of ⁶⁵Zn in the soluble and non-251 soluble fractions.

252

253 2.13. Calculate the proportion of the radio isotopes of Zn (⁶⁵Zn) present in the soluble and non-254 soluble fractions.

255

256 3. Evaluation of Zn chemical species uptake using an in vitro intestinal model (RTgutGC)

257

258 **3.1. RTgutGC cells culture**

259

NOTE: All working materials used in this step should be sterile.

261

3.1.1. Revive the frozen RTgutGC cells gently in a water bath set at 20 °C.

263

3.1.2. Gently pipette out the solution containing the cells and suspend them in 10 mL of L15

265 medium containing 10% fetal bovine serum (FBS). 266 267 NOTE: 10% FBS is only used for reviving the frozen cells. For subsequent passage, FBS is used at 268 5%. The composition of FBS can vary between batches, so it is advisable to buy and stock as much 269 as required from a single batch to avoid inter-batch variations in the serum composition. 270 271 3.1.3. Add the cell suspension to 75 cm² cell culture flasks and incubate in an incubator set at 19 272 °C under normal atmosphere. 273 274 3.1.4. Check the cells and when confluent (80% confluence, assess visually by examining the 275 density of the cell surface under a microscope), split the cells to new flasks (subsequent passage) 276 or harvest to use in experiments. 277

NOTE: An example of the RTgutGC cells 1 h and 1 week after seeding to the cell culture flasks is shown in **Figure 3**.

3.2. Cell harvest and preparing for exposure experiments

280 281

282283

284

285

286287

290291

292

297298

299300

301

304 305

306

3.2.1. Wash cells twice with 1 mL ethylenediaminetetraacetic acid (EDTA) solution. After each wash, siphon out the EDTA solution using a sterile suction tube.

3.2.2. Treat the cells with trypsin (0.7 mL of trypsin, in 0.25% in phosphate-buffered saline [PBS]).

3.2.3. Gently rotate the flask at acute angles to spread the trypsin all along the surface of the flask.

3.2.4. Continue rotation for 2 min, while the cells detach.

293 3.2.5. After gently rotating for 2 min, add 10 mL of L15/FBS medium to neutralize trypsin.
294

295 3.2.6. Decant the resulting cell suspension into a conical bottom centrifuge tube using a sterile pipette and centrifuge for 3 min at 130 x g.

3.2.7. Determine the density of the harvested cells by manual counting using hemocytometer.

3.2.8. Add required volume of L15/FBS medium to attain a cell density of 5 x 10⁴ cells/mL.

302 3.2.9. Seed the cells onto 24-well plates by pipetting 1 mL of cell suspension per well to attain the final cell density of 5 x 10⁴ cells/well.

NOTE: Preferably use multi-dispensing pipettes to minimize variation and reduce time.

3.2.10. Place the seeded plates in an incubator under normal atmosphere at 19 °C for 48 h prior
 to experiments.

309 310 NOTE: Trypsin to be stored at -20 °C; EDTA solution and L15/FBS media at 4 °C. Adjust 311 temperature of all working solutions and media to 19 °C just before use. 312 313 3.3. Preparation of exposure media 314 315 NOTE: This step has to be done under the fume hood under aseptic and sterile conditions. 316 317 3.3.1. Prepare L15/ex by mixing 6.8 mL of salt solution A (step 2.3.1), 1.14 mL of B (step 2.3.2), 5 318 mL of C (step 2.3.3), and 1.14 mL each of pyruvate (step 2.3.6) and galactose (step 2.3.7). Make up the volume to 100 mL using sterile cell culture-grade distilled water.

319320

- 3.3.2. Prepare FW by mixing 6.8 mL of salt solution A (2.3.1), 4.14 mL of B (2.3.2), 5 mL of C (2.3.3),
- 322 2.5 mL of D (2.3.4), 1.5 mL of E (2.3.5), and 1.14 mL each of pyruvate (2.3.6) and galactose (2.3.7).
- 323 Make up the volume to 100 mL using sterile, cell culture-grade distilled water.

324

3.3.3. Quantify the concentrations of ions in the exposure media using ICP-MS as described elsewhere¹².

327

NOTE: Ionic concentrations analyzed in the media preparations are presented in **Table 2**.

329 330

3.4. Zinc (65Zn) influx assays

331

332 3.4.1. Seed the RTgutGC cells onto 24-well plates (5 x 10⁴ cells/well) in complete L15/FBS medium.

333

334 3.4.2. Incubate for 48 h in an incubator with normal atmosphere at 19 °C.

335

3.4.3. Adjust all experimental media preparations to pH 7.4 using 0.5 M NaOH in the presence or absence of L-methionine (L-Met) or DL-methionine (DL-Met) at 2 mM concentration.

338

NOTE: The pH adjustment of the buffers described in 3.4.3 needs to be done freshly before treatment of the cells in step 3.4.5.

341

3.4.4. After the completion of the incubation period, remove the medium from the wells, and rinse thoroughly with PBS.

344

3.4.5. Add the pH-adjusted FW experimental media, and allow to acclimatize for 20 min.

346

3.4.6. Expose the RTgutGC cells to nominal concentrations of 3.07, 6.14, 12.27 and 24.55 μ M of 5Zn(II) (as ZnCl₂; ~4 kBg/mL) in the media described in step 3.4.3.

349

350 3.4.7. Immediately after, keep the cells in the incubator at 19 °C for 15 min.

351

352 3.4.8. After the 15 min incubation is over, aspirate the culture supernatant and remove from the

3.4.9. Rinse the cells with ice cold FW medium (with 200 μ M Zn, pH 7.4) and then quench by adding the 5 mM ethylene glycol-bis(β -aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) buffer (pH 7.4) for 5 min, to get rid of any adsorbed ⁶⁵Zn(II).

3.4.10. Expose the cells to the above media preparations in the presence or absence of 10 mM 2-Aminobicyclo [2.2.1] heptane-2-carboxylic acid (BCH), an amino acid transport inhibitor.

3.4.11. After the exposure period of 15 min, repeat steps 3.4.8 and 3.4.9.

3.4.12. The RtgutGC cells will be adhered to the bottom of the wells as a monolayer. Digest the cells by using 0.2% hot sodium dodecyl sulfate (SDS) detergent (100 µL/well).

NOTE: The SDS solution needs to be placed for 1 h in a water bath set to 90 °C prior to use.

369 3.4.12. Aspirate and recover the cell digestate into a 1.5 mL tube.

371 3.4.11. Measure radioactivity of the cell digests using a gamma counter.

NOTE: The counts per minute (cpm) needs to be corrected for radioactive decay, background activity and are subjected to specific activity calculations following the formulae described by Glover and Hogstrand¹³.

3.4.12. To quantify the protein concentration of the cells, homogenize the cells with 500 μL of 0.5 M NaOH.

3.4.13. Use a Bradford assay kit to measure the protein concentration in the cell sample, with bovine serum albumin (BSA) as the standard.

NOTE: Once the protein concentration is quantified, the rate of Zn uptake by RTgutGC cells can be expressed as pmoles Zn min⁻¹ mg⁻¹ protein.

4. Apparent availability of dietary Zn in Atlantic salmon (Salmo salar)

NOTE: The Atlantic salmon feeds were formulated based on commercial feeds, containing protein sources mainly from plant-based ingredients (i.e., approximately 5% fish protein, 10% fish oil, 68% plant-based protein and 12% plant oil). Two feeds were supplemented with an inorganic source (Zn sulphate) or an organic source (Zn chelate of glycine) to achieve a Zn concentration of 150 mg/kg of feed. In addition, Yttrium oxide (feed grade) was added to the feed at 0.01% as the inert marker to enable calculation of apparent availability coefficient.

4.1. Acclimatize the Atlantic salmon (SalmoBreed strain, age 1+ years, mixed-sex groups) in their
 respective tanks until the fish are used to the experimental conditions.

397 398

4.2. Assess the acclimation of the Atlantic salmon by monitoring their daily feed intake.

399

400 NOTE: This trial was performed in triplicate tanks, thus a total of six tanks were used. During the 401 feeding trial the water temperature was 11.9 \pm 0.3 °C and dissolved oxygen saturation was 101 \pm 402 5%.

403

404 4.3. Feed the fish with experimental feeds for 11 days.

405

406 4.4. Euthanize the fish by overdose using 6 mL of tricaine methanesulphonate stock solution per 407 liter of water.

408

409 4.5. Collect a pooled sample of feces from the fish from the same tank into a plate by striping 410 from the ventral fin to anus.

411

412 4.6. Remove the feces from the plate with a spatula into a 50 mL conical tube and immediately 413 store the samples at -20 °C.

414

415 NOTE: The samples were kept at -20 °C until further analysis.

416

417 4.7. Freeze dry the feces samples for 72 h at -80 °C.

418

419 4.8. Manually homogenize manually the feces sample into a fine powder using a pestle and 420 mortar.

421

422 4.9. Determine the concentration of Zn and Yttrium in the feed and feces samples using an ICP-423 MS (as described elsewhere⁹).

424

425 4.10. Determine apparent availability coefficient (AAC, %) using the following formula:

426
$$AAC (\%) = 100 - \left(100 \frac{\text{Yttrium in feed}}{\text{Yttrium in faeces}} * \frac{\text{Zn in faeces}}{\text{Zn in feed}}\right)$$

427 428

REPRESENTATIVE RESULTS:

429

430 Evaluation of Zn chemical species in the soluble fraction of an Atlantic salmon feed using a SEC-431 **ICP-MS** method

- 432 The SEC-ICP-MS method provides data about the Zn chemical species found in the soluble
- 433 fraction of the Atlantic salmon feed. Figure 4 illustrates the chromatographic profile of Zn found 434 in the soluble fraction. This chromatogram was obtained using the SEC-ICP-MS method. Five Zn
- 435 containing peaks were found in the soluble fractions of the Atlantic salmon feed. Each peak has
- 436 a different molecular weight; peak one (~ 600 kDa), peak two and peak three (from 32 to 17 kDa),
- 437 peak four (from 17 to 1.36 kDa) and peak five (> 1.36 kDa). Peak four was the most abundant,
- 438 followed by peak two, three, five and one, respectively. The Zn chemical species found in the

soluble fraction can have different sources because the feed used contains both marine-based and plant-based ingredients, and supplemented form (i.e., Zn sulphate). The molecular weight range of the Zn chemical species suggested that these compounds might be metalloproteins.

In vitro solubility of supplemented Zn in Atlantic salmon feed

Solubility of supplemented ⁶⁵Zn increased in the presence of amino acids. All the tested amino acids increased the solubility of supplemented ⁶⁵Zn. Methionine, glycine, cysteine, histidine, and lysine improved ⁶⁵Zn solubility; higher solubility was found with histidine and lysine (**Figure 5**).

Evaluation of Zn species uptake using an in vitro intestinal model (RTgutGC)

Apical zinc uptake in RTgutGC cells were significantly influenced by the presence of L-Met or DL-Met at 2 mM concentrations. Furthermore, the impact of methionine on Zn uptake in RTgutGC cells was negatively affected by the presence of BCH (an amino acid transport system blocker), when compared to cells untreated with BCH (Figure 6).

Apparent availability of dietary Zn in Atlantic salmon (Salmo salar)

In practical feeds for Atlantic salmon, apparent Zn availability was the same when supplementing with an inorganic source (Zn sulphate) or an organic source (Zn chelate of glycine). The estimated values for apparent availability of Zn (%, n = 3) in Atlantic salmon were 31% \pm 12% when supplementing with an inorganic source (Zn sulphate) and 31% \pm 3% when supplementing an organic source (Zn chelate of glycine).

FIGURE AND TABLE LEGENDS:

Figure 1: A summary of the systematic approach to assess mineral availability using complementary methods. This approach was used to study zinc availability in Atlantic salmon, including Zn speciation, Zn solubility in intestinal environment, Zn uptake by intestinal cells and Zn apparent availability.

Figure 2: A summary of the procedure for Zn extraction from a feed sample. Zinc is extracted from a feed sample using mild extraction conditions. The extraction is followed by Zn speciation analysis.

Figure 3: An example of the RTgutGC cells 1 h (left) and 1 week (right) after seeding in the cell culture flasks.

Figure 4: A chromatogram showing the Zn-containing peaks from the soluble fraction of Atlantic salmon feed and analyzed by SEC-ICP-MS. The three replicates are characterized by the blue, red and black lines. A molecular weight calibration was performed using thyroglobulin (660 kDa, monitoring ¹²⁷I), Zn/Cu superoxide dismutase (32 kDa, monitoring ⁶⁶Zn), myoglobin (17 kDa, monitoring ⁵⁷Fe), vitamin B12 (1.36 kDa, monitoring ⁵⁹Co); Peak 1 (P1): ~600 kDa, retention time (RT) 8.2 min; Peak 2+3 (P2+3): from 32 to 17 kDa, RT 14.2 + 15.3 min; Peak 4 (P4): from 17 to 1.36 kDa, RT 16.3 min; Peak 5 (P5): > 1.36 kDa, Rt 23.2 min.

 Figure 5: The impact of amino acids on the in vitro solubility of supplemented Zn in Atlantic salmon feed. Data are presented as mean \pm SD (n = 3). Data were analyzed through one-way ANOVA, followed by Dunnet's multiple comparison test, comparing the mean of each AA group with that of control group (No AA). The asterisks denote the level of significance of ANOVA (P-values < 0.05 (*), < 0.01 (***), < 0.001 (***) and < 0.0001 (****)).

Figure 6: The influence of methionine and an amino acid transport inhibitor (2-Aminobicyclo [2.2.1] heptane-2-carboxylic acid, BCH, 10 mM). Data are presented as mean \pm SD (n = 3). Data were analyzed through two-way ANOVA, followed by Tukey's multiple comparison test with p < 0.05 level of significance. Post-hoc differences among groups are represented as superscript letter above the bars; bars with different superscripts are statistically different (p < 0.05).

Table 1. An overview of instrument settings for the HPLC and ICP-MS.

Table 2. The chemical and ionic composition of the experimental media tested.

DISCUSSION:

The intestinal absorption of Zn seems to be influenced by the chemical form of the Zn species¹³. In this regard, the use of the protocols described in this article allowed the sequentially study of the chemical and biological aspects underlying the 'availability' of Zn in Atlantic salmon.

This study reported the use of a Zn speciation analysis method. The SEC-ICP-MS method provided qualitative data concerning the molecular weight of Zn chemical species present in the soluble fraction of an Atlantic salmon feed. This was achieved by comparison of the retention times of the molecular weight calibration standards (i.e., thyroglobulin (660 kDa), Zn/Cu superoxide dismutase (32 kDa), myoglobin (17 kDa) and vitamin B12 (1.36 kDa)) with the retention times of Zn containing peaks. A challenge found in the Zn speciation analysis was the identification of the unknown Zn chemical species due to lack of analytical standards. In SEC, the separation of the molecules is based on their sizes relative to the pores in the stationary phase. In principle, larger molecules will travel faster, eluting first, and smaller molecules will travel slower, eluting later¹⁴. Consequently, each Zn containing peak might contain several compounds with similar molecular weight¹⁵. This also contributes to the challenge of identifying unknown Zn chemical species. Moreover, several mild extraction conditions were tested for extraction of Zn. The extracted Zn was low (~10%). Mild extraction conditions were applied to keep the Zn chemical species intact but this may have compromised the extraction efficiency⁷.

In the in vitro solubility assay, the solubility of supplemented Zn (as radio isotope ⁶⁵ZnCl₂) indicated that the amino acids, especially histidine and lysine, increased the solubility of Zn (**Figure 5**). Using feed samples directly for in vitro solubility assays under simulated gastrointestinal conditions is based on the knowledge that change in Zn speciation is pH dependent¹⁶. However, acidic conditions at the beginning of the GI tract, might result in some change in the speciation which might be irreversible (e.g., ZnO -> ZnCl₂, in the presence of HCl under acidic conditions in the stomach). Nevertheless, the Zn source used here is ZnSO₄ and the solubility of which was improved by amino acids in the medium. The next question to be

answered was, can the increased solubility be translated to availability? The RTgutGC intestinal cell line was used to study this question. In the context of mineral nutrition in animals, the term 'availability' is hard to define and can be regulated differentially in the cells (in vitro) compared to an animal (in vivo). Hence, the term 'uptake' was used when it came to the in vitro evaluation using intestinal cell line. The cell line provided useful information on the Zn uptake mechanisms at the intestinal epithelium which is part of the complex regulatory process which govern mineral availability in animals. The RTgutGC cells elicited a better capacity for apical uptake of Zn in the presence of an amino acid (i.e., methionine; **Figure 6**). However, the apparent availability in vivo did not significantly differ between inorganic and organic Zn sources in Atlantic salmon. In the in vivo availability study, the Zn source comparison was made at dietary Zn levels well exceeding the known Zn requirements of Atlantic salmon¹⁷, total Zn concentration of 150 mg/kg feed. The differences in availability are better visualized when the dietary levels tested fall in the linear dynamic range before the animal reaches saturation. In the present in vivo study, it is possible that the Atlantic salmon were well saturated to observed difference in Zn absorption between sources used.

In summary, the first method provided qualitative information regarding different Zn chemical species found in the soluble fraction of an Atlantic salmon feed; the second method, in vitro solubility of supplemented Zn was improved in the presence of amino acid ligands; the third method confirmed that improved solubility by amino acids can improve uptake at intestinal epithelium; conversely, the fourth method failed to find differences in availability of Zn from inorganic or organic source to Atlantic salmon. To conclude, although not in alignment with the in vivo findings, the in vitro protocols did provide interesting insights into understanding the different components of the Zn availability.

ACKNOWLEDGMENTS:

This work was performed under the project APREMIA (Apparent availability and requirement of minerals in Atlantic salmon, grant no. 244490) funded by the Norwegian Research Council.

DISCLOSURES:


The authors have nothing to disclose.


REFERENCES:


- Ytrestoyl, T., Aas, T. S., Asgard, T. Utilisation of feed resources in production of Atlantic salmon (*Salmo salar*) in Norway. *Aquaculture*. **448** 365-374, (2015).
- Prabhu, P. A. J. *et al.* Evaluating dietary supply of microminerals as a premix in a complete plant ingredient-based diet to juvenile rainbow trout (*Oncorhynchus mykiss*). *Aquaculture Nutrition*. **24** (1), 539-547 (2018).
 - Maret, W. Zinc biochemistry: from a single zinc enzyme to a key element of life. *Advances in nutrition (Bethesda, MD).* **4** (1), 82-91 (2013).
- Hogstrand, C. in *Fish Physiology* Vol 31. Edited by Chris M. Wood, Anthony P. Farrell, Colin J. Brauner, 135-200. Academic Press (2011).
- 569 5 Baeverfjord, G. *et al.* Mineral nutrition and bone health in salmonids. *Reviews in Aquaculture.* 570 (2018)


- 571 6 Maage, A., Julshamn, K. Assessment of zinc status in juvenile Atlantic salmon (Salmo salar) by 572 measurement of whole body and tissue levels of zinc. *Aquaculture*. **117** (1), 179-191 (1993).
- 573 7 Silva, M. S., Sele, V., Sloth, J. J., Araujo, P., Amlund, H. Speciation of zinc in fish feed by size 574 exclusion chromatography coupled to inductively coupled plasma mass spectrometry – Using 575 fractional factorial design for method optimization and mild extraction conditions. *Journal of* 576 *Chromatography B* (2018).
- 577 8 Antony Jesu Prabhu, P. *et al.* Zinc uptake in fish intestinal epithelial model RTgutGC: Impact of media ion composition and methionine chelation. *Journal of Trace Elements in Medicine and Biology.* **50**, 377-383 (2018).
- 580 9 Silva, M. S., *et al.* Apparent availability of zinc, selenium and manganese as inorganic metal salts or organic forms in plant-based diets for Atlantic salmon (Salmo salar). *Aquaculture.* **503,** 562-570 (2019).
- Persson, D. P., Hansen, T. H., Laursen, K. H., Schjoerring, J. K., Husted, S. Simultaneous iron, zinc, sulfur and phosphorus speciation analysis of barley grain tissues using SEC-ICP-MS and IP-ICP-MS. *Metallomics.* **1** (5), 418-426 (2009).
- 586 11 Lothian, A., Roberts, B. R. Standards for Quantitative Metalloproteomic Analysis Using Size Exclusion ICP-MS. *Journal of Visualized Experiments.* **110,** 1-8 (2016).
- 588 12 Minghetti, M., Schirmer, K. Effect of media composition on bioavailability and toxicity of silver 589 and silver nanoparticles in fish intestinal cells (RTgutGC). *Nanotoxicology.* **10** (10), 1526-1534 590 (2016).
- 591 Glover, C. N., Hogstrand, C. Amino acid modulation of in vivo intestinal zinc absorption in freshwater rainbow trout. *Journal of Experimental Biology.* **205** (1), 151-158 (2002).
- 593 14 Ekman, R. in *Mass spectrometry: Instrumentation, interpretation, and applications. Wiley Series* 594 on *Mass Spectrometry*. Edited by Rolf Ekman. 105-115. John Wiley & Sons (2009).
- Hong, P., Koza, S., Bouvier, E. S. P. A Review Size-Exclusion Chromatography for the Analysis of
 Protein Biotherapeutics and Their Aggregates. *Journal of Liquid Chromatography & Related Technologies.* 35 (20), 2923-2950 (2012).
- Krezel, A., Maret, W. The biological inorganic chemistry of zinc ions. *Archives of Biochemistry and Biophysics.* **611**, 3-19 (2016).
- National Research Council. *Nutrient Requirements of Fish and Shrimp*. The National Academies Press. (2011).

602











Freshwater (5mM AAs)





HPLC settings

Column

Calibration range

Mobile phase

Flow rate

Injection volume

ICP-MS settings

Forward power

Plasma gas flow

Carrier gas flow

Makeup gas flow

Dwell time

Isotopes monitored

SEC column

(30 cm x 7.8 mm, 5 μ m particle size) + guard column (7 μ m

 $1.0 \times 10^4 - 5.0 \times 10^5$ Da

50 mM Tris-HCl + 3% MeOH (pH 7.5)

0.7 mL min⁻¹

50 μL

1550 W

15.0 L min⁻¹

0.86 L min⁻¹

 $0.34 \, \text{L min}^{-1}$

0.1 s per isotope

¹²⁷I, ⁶⁶Zn, ⁵⁹Co, ⁵⁷Fe

Chemical composition (mM)	L15/ex
Sodium nitrate	155
Potassium nitrate	6.2
Magnesium sulfate	3.8
Calcium nitrate	1.5
HEPES	5
Magnesium chloride	-
Sodium pyruvate	5.7
Galactose	5.7
pH	7.1
Ionic strength	178
Ionic composition (mM)	
Calcium, Ca ^{2+ *}	1.6 ± 0.1
Magnesium, Mg ^{2+ *}	3.9 ± 0.3
Potassium, K [*]	8.2 ± 1.2
Sodium, Na ^{+ *}	160 ± 3
Nitrate, NO ₃ ^{-**}	164
Sulfate, SO ₄ -**	3.8
Chloride, Cl ^{-**}	1.5

Experimental medium (L15/FW)		
155		
6.2		
19.5		
5.4		
5		
15		
5.7		
5.7		
7.4		
258		
5.3 ± 0.2		
32.5 ± 0.7		
8.6 ± 1.1		
157 ± 2		
172.4		
18.7		
10.7		

31.5

Name of Material/ Equipment	Company	Catalog Number
0.45 μm syringe filter	Sartorius	
0.45 μm membrane filter	Pall	
10 % fetal bovine serum	Eurobio	
1282 Compugamma Laboratory Gamma Counter	LKB Wallac	
24 well plates (Falcon, TPP microplates)	Thermo Fisher Scientific	10048760
2-aminobicyclo(2.2.1)heptane-2-carboxylic acid	Sigma Aldrich	A7902
75 cm ² cell culture flasks (Falcon, TPP tissue culture flasks)	TPP Techno Plastic Products AG	90075
L-Arginine	Sigma Aldrich	A5006
Bradford assay kit	Bio-Rad	5000001
Centrifuge	Eppendorf Centrifuge 5702	
L-Cysteine	Sigma Aldrich	30089
DL-methionine	Alfa Aesar	59-51-8
D-methionine	Sigma Aldrich	M9375
Experimental fish feeds	Skretting	
Glycine	Sigma Aldrich	410225
Guard column, TSKgel SWxl Type (7 μm particle size)	Tosoh	
L-Histidine	Sigma Aldrich	53319
HPLC coupled with a 7500ce ICP-MS	Agilent Technologies	
Hydrochloric acid	Emsure ACS, ISO, 37% w/w, Merck	1.00317
Knife mill	GM 300, Retsch Gmbh	
L-15 medium	Invitrogen/Gibco	21083027
L-methionine	Sigma Aldrich	M9625
L-Lysine	Sigma Aldrich	23128
Methanol	LiChrosolv, HPLC grade, Merck	1.06035
Milli-Q water (18.2 MΩ cm)	EMD Millipore Corporation	
Myoglobin	Sigma Aldrich	M1882
NexION 350D ICP-MS	Perkin Elmer	
Pasteur pipette	VWR	
pH meter	inoLab	
Phosphate-buffered saline (PBS)	Sigma Aldrich	806552
RTgutGC cells		

Tosoh	
Retsch	
Sigma Aldrich	436143
Sigma Aldrich	S7571
Sigma Aldrich	T1001
PharmaQ	
Sigma Aldrich	252859
Biowest	L0910
Invitrogen/Gibco	15040-033
Sigma Aldrich	V2876
Phytobiotics	
Vilomix	
	Retsch Sigma Aldrich Sigma Aldrich Sigma Aldrich PharmaQ Sigma Aldrich Biowest Invitrogen/Gibco Sigma Aldrich Phytobiotics





ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	A cross-disciplinary approach to study mineral availability in fish feeds: example of zinc in Atlantic salmon
Author(s):	Marta S Silva, Heidi Amlund, Jens J Sloth, Erik-Jan Lock, Robin Ørnsrud, Rune Waagbø, Antony Jesu Prabhu
•	box): The Author elects to have the Materials be made available (as described at ove.com/author) via: Standard Access Open Access
Item 2 (check one bo	x):
The Aut	or is NOT a United States government employee. nor is a United States government employee and the Materials were prepared in the or her duties as a United States government employee.
	or is a United States government employee but the Materials were NOT prepared in the or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

- 1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found http://creativecommons.org/licenses/by-ncnd/3.0/legalcode; "Derivative Work" means a work based upon the Materials or upon the Materials and other preexisting works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.
- 2. <u>Background</u>. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.
- 3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



ARTICLE AND VIDEO LICENSE AGREEMENT

- 4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.
- 5. <u>Grant of Rights in Video Standard Access</u>. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.
- 6. Grant of Rights in Video Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.
- 7. <u>Government Employees.</u> If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

- statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.
- 8. <u>Likeness, Privacy, Personality</u>. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.
- 9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.
- 10. <u>JoVE Discretion</u>. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

- 12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.
- 13. <u>Transfer, Governing Law</u>. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Antony Jesu Prabhu			
Department:	Fish nutrition: requirement and welfare			
Institution:	Institute of Marine Research, Bergen, Norwa	ay		
Article Title:	rticle Title: A cross-disciplinary approach to study mineral availability in fish feeds: example of zinc in Af			salmor
Signature:	Antony	Date:	04.12.2018	

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pfd on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For guestions, please email submissions@jove.com or call +1.617.945.9051

REBUTTAL LETTER

Antony Jesu Prabhu, P Senior Researcher, Fish Nutrition: Requirement & Welfare group, Institute of Marine Research, Bergen, Norway.

To,

The Editor,

JoVE.

30.04.2019.

Subject: Submission of revised version of our manuscript for peer-review in JoVE.

Dear Editor,

Following the editorial comments received on the previous version of our submission, I am pleased to re-submit the revised version of the manuscript 'Systematic approach to assess mineral availability in fish feeds using complementary methods, an example of zinc in Atlantic salmon (Salmo salar)'.

The editorial comments and suggestions made have been revised in detail and the revisions can be tracked in the version attached.

We believe that the manuscript in the present form fulfils the requirement of the journal.

Thanking you,

Yours truly,

Antony Jesu Prabhu, P, on behalf of co-authors